• By ICR Secretariat
  • Posted Thursday, June 3, 2021

A hugely consequential decision:' How Biogen's Alzheimer's drug came to face the FDA

https://www.biopharmadive.com/news/biogen-aducanumab-alzheimers-fda-drug-review/600897/

By June 7, the regulator will decide on whether to approve aducanumab, a decision that could have far-reaching consequences for patients, Biogen and Alzheimer's research.